Affimed to Present Data on NK- and T-Cell Engagers at ASH
HEIDELBERG, Germany, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that two of the Company's abstracts have been chosen for …